Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (5 quarters reported)
$101M in Q4 2017 → $38.1M now. Hover for any quarter.
As reported for the quarter ended December 31, 2018. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc | 62.0% | Unchanged | 1,790,102 | $23.6M |
| Verona Pharma PLC | 22.2% | Unchanged | 875,000 | $8.44M |
| MT Menlo Therapeutics Inc. | 15.8% | Unchanged | 1,461,552 | $6.02M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 4 quarters.
quarter ended December 31, 2018 · filed February 14, 2019
No position changes this quarter.
quarter ended September 30, 2018 · filed November 14, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc | Trimmed | −1,504,552 | −$26.8M | 55.7% |
| Nabriva Therapeutics PLC | Exited | −177,957 | −$619K | — |
quarter ended June 30, 2018 · filed August 14, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Nabriva Therapeutics PLC | Trimmed | −1,945,005 | −$6.77M | 0.6% |
| Apellis Pharmaceuticals, Inc | Trimmed | −284,651 | −$6.26M | 74.8% |
quarter ended March 31, 2018 · filed April 25, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| MT Menlo Therapeutics Inc. | New | +1,461,552 | +$54.9M | 33.9% |
Loading...
